Osang Healthcare Co.,Ltd (036220.KQ)
KRW 11870.0
(-2.63%)
KRW 11870.0
(-2.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 116.43 Billion KRW | 186.46% |
| 2022 | 40.64 Billion KRW | 2683.22% |
| 2021 | 1.46 Billion KRW | -98.83% |
| 2020 | 124.99 Billion KRW | 3058.93% |
| 2019 | -4.22 Billion KRW | -296.82% |
| 2018 | 2.14 Billion KRW | -75.74% |
| 2017 | 8.84 Billion KRW | 181.17% |
| 2016 | -10.9 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5.83 Billion KRW | -539.93% |
| 2024 Q1 | 1.32 Billion KRW | 133.0% |
| 2023 Q1 | 121.01 Billion KRW | 2068.86% |
| 2023 Q4 | -4.01 Billion KRW | 16.58% |
| 2023 Q3 | -4.81 Billion KRW | -213.08% |
| 2023 Q2 | 4.25 Billion KRW | -96.48% |
| 2023 FY | 116.43 Billion KRW | 186.46% |
| 2022 Q2 | 13.22 Billion KRW | -52.85% |
| 2022 FY | 40.64 Billion KRW | 2683.22% |
| 2022 Q4 | -6.14 Billion KRW | -211.04% |
| 2022 Q3 | 5.53 Billion KRW | -58.13% |
| 2022 Q1 | 28.03 Billion KRW | 857.2% |
| 2021 Q3 | 1.26 Billion KRW | 0.0% |
| 2021 FY | 1.46 Billion KRW | -98.83% |
| 2021 Q4 | -3.7 Billion KRW | -393.36% |
| 2020 FY | 124.99 Billion KRW | 3058.93% |
| 2019 FY | -4.22 Billion KRW | -296.82% |
| 2018 FY | 2.14 Billion KRW | -75.74% |
| 2017 FY | 8.84 Billion KRW | 181.17% |
| 2016 FY | -10.9 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| InBody Co.,Ltd | 36.72 Billion KRW | -217.067% |
| Curexo Inc. | -4.85 Billion KRW | 2497.762% |
| Seegene, Inc. | 669.01 Million KRW | -17304.145% |
| i-SENS, Inc. | 3.7 Billion KRW | -3039.223% |
| Ray Co., Ltd. | -2.14 Billion KRW | 5524.904% |
| Gencurix Inc. | -19.26 Billion KRW | 704.546% |
| Sugentech Inc. | -17.23 Billion KRW | 775.449% |
| L&C Bio Co., Ltd | 48.36 Billion KRW | -140.764% |